Peptide Combinations: What Is Studied Together and Why

Start with what has not been shown

More is missing than is known about peptide combinations, so this page begins there. None of the following has been demonstrated in the published literature.

• A benefit in people. Not one combination described here has gone through a published randomised controlled trial, whatever the outcome measured.
• That a larger GH peak carries through. The human studies of growth hormone-releasing hormone (GHRH) with a growth hormone releasing peptide (GHRP) recorded growth hormone (GH) in the hours after one dose and went no further. Nobody measured whether the extra GH became extra IGF-1, a change in body composition or quicker recovery.
• That CJC-1295 with ipamorelin behaves like the older pairs. This particular pair has no published controlled trial. Its rationale is borrowed from work with GHRH and GHRP-6.
• That rodent repair data carry over to human tissue. This is unproven for BPC-157 alone, for thymosin beta-4 alone, and all the more for the two together.
• That the risks are understood. BPC-157 and thymosin beta-4 both promote blood-vessel formation in animal work. Tumours depend on that process too, so an untested theoretical concern hangs over each peptide and over the pair. Long-term safety data exist for no combination here.

Online user reports do not close these gaps. They have no control group, no verified dose and no check on what the vial contained.

What would count as evidence for a pair

Putting two peptides together creates something that has to be studied in its own right: how it acts, how dose relates to response, and what can go wrong. Results for peptide A and results for peptide B do not merge into results for A plus B. A combination study asks two things. Does the pair do something neither member does alone, and is the joint effect bigger than the two single effects summed? Pharmacologists call the second case more than additive. Demonstrating it takes four arms in one experiment: vehicle, A alone, B alone, and A with B.

The case for a given pair tends to take one of three forms. Both peptides push on the same process from different sides, and each strengthens the other. Or they work on different processes that end in the same result, as new blood vessels and migrating cells both serve a wound. Or the second peptide patches a shortcoming of the first, such as a brief half-life. Of the pairings below, only the first form has solid human data, and only for an acute hormone read-out.

The pairing with human data: GHRH plus a ghrelin mimetic

Two hypothalamic hormones set GH release from the pituitary: GHRH drives it and somatostatin restrains it. Ghrelin, a stomach hormone, adds a third signal via the receptor GHS-R1a. CJC-1295 and tesamorelin are GHRH analogues: they bind the GHRH receptor and raise cyclic AMP inside the GH-producing cell. Ipamorelin, GHRP-2 and GHRP-6 are ghrelin mimetics: they bind GHS-R1a, which works through phospholipase C and intracellular calcium instead.

From around 1990 onwards, human studies gave GHRH and GHRP-6 together, usually as one intravenous dose, and recorded more GH than the two separate responses added up to. Other GHRPs behaved alike, and the response proved dependable enough to become a stimulation test for GH deficiency. Three explanations are given. Cyclic AMP and calcium are separate signals, and inside one cell each strengthens the other. The ghrelin mimetic also reaches the hypothalamus, which answers by releasing more of its own GHRH. And it weakens somatostatin, the brake that normally caps the amount of GH a GHRH signal frees. The hypothalamic route is needed: when the pituitary has lost its connection to the hypothalamus, GHRP-6 releases very little GH.

Evidence level: acute human physiology, sound and narrow. The pairing sold most today puts CJC-1295 with ipamorelin. Ipamorelin became the preferred partner because in pigs it left ACTH and cortisol alone, which GHRP-6 and GHRP-2 do not, and because it lacks the marked appetite effect of GHRP-6. The newer pair has a timing problem that the older studies did not. CJC-1295 with the DAC linker stays active for days, while ipamorelin has a terminal half-life of about two hours, so dosing both together does not recreate the simultaneous pulses of the physiology studies. The secretagogue comparison covers the single compounds.

The repair pair: BPC-157 and TB-500

Here the argument is of the second form: two routes to one result. Animal and cell studies tie BPC-157, a 15-amino-acid peptide, to blood-vessel growth driven by VEGF and to nitric oxide signalling; its receptor, if it has one, is unidentified. Thymosin beta-4, the peptide behind the trade name TB-500, binds actin monomers and promotes cell migration. Rodent experiments report faster healing with either one, and the hope is that the two routes add up.

It remains a hope. Formal combination studies, with each compound tested alone and both together in one model, are scarce in animals and absent in humans. Most BPC-157 work comes from one research group in Zagreb, replication elsewhere is limited, and no randomised controlled trial in humans has been published. For thymosin beta-4 the human data are small early trials of pharmaceutical formulations (eye drops, a topical gel, an intravenous phase 1 study), none of which became a medicine. No published controlled human study has used a product sold under the TB-500 name.

There is an identity problem on top. TB-500 is a commercial name, used for full-length thymosin beta-4, 43 amino acids and about 4963 Da, and also for short fragments built around the actin-binding motif LKKTETQ, which weigh a little under 900 Da. Findings with the full peptide say nothing certain about a fragment, and the reverse holds too.

Pairings at a glance

Row four shows how drug developers handled the same idea: they built a single molecule and ran it through large randomised trials. Tirzepatide and retatrutide are the result, and the GLP-1 agonist guide compares them. No research-peptide combination has been through anything comparable.

Three blends, by their exact shop names

King Peptides lists three premixed products, each with a fixed composition.

• CJC-1295 + Ipamorelin Blend 5/5 mg. Contains 5 mg of the GHRH analogue and 5 mg of the ghrelin mimetic, and is the only form in which the shop lists either peptide. Whether the CJC-1295 is the DAC form cannot be read from the product name. The certificate of analysis (CoA) should show 3647.2 Da with DAC or 3367.9 Da without, next to 711.9 Da for ipamorelin.
• Wolverine Stack - BPC-157 + TB-500 5/5 mg. Again 5 mg per component. BPC-157 has a mass of 1419.5 Da. Full-length thymosin beta-4 comes in at about 4963 Da, the figure to look for if the TB-500 part is the whole peptide.
• KLOW-80 Blend - GHK-Cu + BPC-157 + TB-500 + KPV. Four peptides in one vial. GHK-Cu is the copper-binding tripeptide, BPC-157 and TB-500 are the repair pair, and KPV (Lys-Pro-Val) is the last three residues of alpha-melanocyte-stimulating hormone. KPV research concerns inflammation, gut inflammation models among them, and has been done in cells and animals.

BPC-157 10 mg, TB-500 (Thymosin Beta-4) 5 mg, GHK-Cu 100 mg and Tesamorelin 10 mg are listed as single compounds. Every lot comes with a lot-specific CoA carrying HPLC and mass spectrometry, and the shop’s lab reports page lists HPLC purity of 98% or higher, with 99% or higher for most products. Orders go out from the Netherlands as tracked parcels. Expect 1–2 business days to a Dutch address and 3–5 business days elsewhere in the EU, which takes in Belgium and Luxembourg, without customs clearance inside the EU. The Benelux buying guide covers ordering in more detail.

What a premixed vial decides for you

What a blend offers is convenience: fewer vials to handle and reconstitute. It also makes several decisions that a study design may not want made.

• The ratio is fixed. Raise one dose and the other rises with it. A dose-response curve for a single component, or a test of different ratios, requires the peptides in separate vials.
• The certificate has more to prove. Look for a separate mass for each peptide in the vial. A lone main peak with a purity percentage does not tell you that. The CoA guide shows what a usable document looks like.
• Stability is an open question. A peptide that is stable by itself is not necessarily stable next to another one in solution, and published stability figures for mixtures are hard to find. General handling is in the storage and reconstitution protocol.
• The end point still has to be chosen. Peak GH tells you about pharmacology. IGF-1 levels, body composition and tissue repair each need their own measurement and run on their own timescale.

A blend can serve an exploratory experiment that is content with one ratio. It cannot serve a study that has to tell the components apart.

Status and sport rules in the Benelux

CJC-1295, ipamorelin, BPC-157 and thymosin beta-4 hold no marketing authorisation in the European Union, so none is an authorised medicine in the Netherlands, Belgium or Luxembourg. Tesamorelin is approved in the United States as Egrifta and is not authorised in the EU. Research material is not sold for human use, and national and institutional rules on possession and import differ and need checking. The WADA Prohibited List has carried BPC-157 by name since 2022, in section S0, and GH secretagogues, GHRH analogues, and thymosin beta-4 with derivatives such as TB-500 fall under S2. Both sections apply at all times.

Quick answers

Does evidence for two peptides separately count as evidence for the pair? No. Showing that a pair does more than its parts needs each part alone and the pair together in one experiment.

Which pairing has human data behind it? GHRH given with a GHRP, and for one read-out only: the GH response after a single intravenous dose.

Does the blend name say which form of CJC-1295 is in the vial? No. Look at the product page, and let the measured mass on the CoA settle it: 3647.2 Da points to the DAC form, 3367.9 Da to the form without it.

What is KPV? The tripeptide Lys-Pro-Val, the C-terminal end of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory effects in cells and animals. It has no profile on this site.